Leeds Teaching Hospitals NHS Trust (LTHT), through the National Pathology Imaging Co-operative (NPIC), is playing a critical role in the delivery of the MANIFEST programme. NPIC will provide national pathology infrastructure and domain expertise for this multi-million-pound UK-wide platform for cancer immunotherapy.
In collaboration with 15 academic institutions and 11 industry partners, NPIC will help advance research into cancer immunotherapy, aiding in the development of personalised treatment strategies by leveraging state-of-the-art digital pathology imaging, storage, and analysis capabilities.
“NPIC is thrilled to contribute to the MANIFEST programme. This funding enables us to leverage our expertise and state-of-the-art digital pathology infrastructure to push forward research in cancer immunotherapy. Through collaboration with partners across the UK, we aim to enhance our understanding of how patients respond to treatments and drive improvements in cancer care.”
Dr Matt Humphries, Head of Translational Research
MANIFEST Project Summary
- MANIFEST is funded by the Medical Research Council and the Office for Life Sciences, with additional matched funds from industry.
- As part of the MANIFEST programme, NPIC will help develop a national platform that integrates digital pathology and multiomic data. This platform will support researchers in identifying critical biomarkers, enhancing the ability to tailor immunotherapy treatments to individual cancer patients.
- The MANIFEST programme, aims to better understand cancer patients’ responses to immunotherapy. NPIC’s advanced digital pathology imaging technology will play a key role in storing and analysing multiomic data.
Further information about the government’s funding can be found here: New government tech deals boost the business of cancer detection – GOV.UK (www.gov.uk)
